ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.

NERV Minerva Neurosciences Inc

2,37
0,02 (0,85%)
03 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Minerva Neurosciences Inc NERV NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
0,02 0,85% 2,37 23:16:11
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
2,39 2,36 2,41 2,37 2,35
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
01/5/202413:30GLOBEMinerva Neurosciences Reports First Quarter 2024 Financial..
27/2/202414:04EDGAR2Form 8-K - Current report
27/2/202414:00GLOBEMinerva Neurosciences Receives Complete Response Letter from..
22/2/202413:00GLOBEMinerva Neurosciences Reports Fourth Quarter and Fiscal Year..
22/2/202412:30EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
07/11/202313:30GLOBEMinerva Neurosciences Reports 2023 Third Quarter Financial..
07/11/202313:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
05/10/202322:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/10/202322:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/9/202314:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/9/202314:57EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/9/202322:05EDGAR2Form 8-K - Current report
15/8/202315:28EDGAR2Form ARS - Annual Report to Security Holders
15/8/202315:26EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
15/8/202315:25EDGAR2Form DEF 14A - Other definitive proxy statements
09/8/202323:12EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
04/8/202314:07EDGAR2Form S-3 - Registration statement under Securities Act of..
01/8/202313:30GLOBEMinerva Neurosciences Reports 2023 Second Quarter Financial..
01/8/202313:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/7/202322:18EDGAR2Form SC 13D - General statement of acquisition of beneficial..
28/6/202314:37EDGAR2Form 8-K - Current report
28/6/202314:30GLOBEMinerva Neurosciences Announces $20 Million in Private..
15/5/202313:30GLOBEMinerva Neurosciences Reports 2023 First Quarter Financial..
10/5/202314:00GLOBEMinerva Neurosciences Announces Update on its New Drug..
08/5/202314:30GLOBEMinerva Neurosciences to Report First Quarter 2023 Financial..

Dernières Valeurs Consultées

Delayed Upgrade Clock